SINERGIUM Biotech

CELL AND GENE THERAPY

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

The World News Monitor | April 08, 2020

• 3 Blue-Chip Biotech Stocks Hitting New Highs. A basket of biotech stocks have surged to new highs in recent weeks, lifting the iShares Nasdaq Biotechnology Index Fund ETF (IBB) within 15 points of 2019 resistance.The stock posted an all-time high at $128 in Tuesday’s session, lifting above 2019 resistance at $122. Price action into the second half of 2019 carved a long series of lower highs and lower lows, dropping the stock to a six-year low....

RESEARCH

Nutrition Technologies | September 19, 2022

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...